News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Videos|March 30, 2022

Biomarker Testing in RCC: Current Approaches

Author(s)David Aggen, MD, PhD

David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.

Episodes in this series

EP. 1 Trends in RCC Incidence

EP. 1 Trends in RCC Incidence

EP. 2 RCC Histologies

EP. 2 RCC Histologies

EP. 3 Risk Models and Prognostic Factors

EP. 3 Risk Models and Prognostic Factors

EP. 4 Metastatic RCC: Prognosis and Recent Advances in Care

EP. 4 Metastatic RCC: Prognosis and Recent Advances in Care

EP. 5 Biomarker Testing in RCC: Current Approaches

EP. 5 Biomarker Testing in RCC: Current Approaches

EP. 6 Biomarker Testing: Methodologies, Sample Types, and Emerging Data

EP. 6 Biomarker Testing: Methodologies, Sample Types, and Emerging Data

EP. 7 Prognostic Value of Biomarkers in RCC

EP. 7 Prognostic Value of Biomarkers in RCC

EP. 8 The Role of Genetic Mutations in Prognosis and Decision-Making

EP. 8 The Role of Genetic Mutations in Prognosis and Decision-Making

EP. 9 Comparison of Older First-Line, Single-Agent Therapies

EP. 9 Comparison of Older First-Line, Single-Agent Therapies

EP. 10 Newer First-Line Combination Therapy Options

EP. 10 Newer First-Line Combination Therapy Options

EP. 11 Evolution of Combination Therapy As The Standard of Care

EP. 11 Evolution of Combination Therapy As The Standard of Care

EP. 12 Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

EP. 12 Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

EP. 13 Safety and Efficacy Data: The CheckMate 214 Trial

EP. 13 Safety and Efficacy Data: The CheckMate 214 Trial

EP. 14 Safety and Efficacy Data: The JAVELIN Renal 101 Trial

EP. 14 Safety and Efficacy Data: The JAVELIN Renal 101 Trial

EP. 15 Safety and Efficacy Data: The KEYNOTE-426 Trial

EP. 15 Safety and Efficacy Data: The KEYNOTE-426 Trial

EP. 16 Safety and Efficacy Data: The CheckMate 9ER Trial

EP. 16 Safety and Efficacy Data: The CheckMate 9ER Trial

EP. 17 Safety and Efficacy Data: The CLEAR Trial

EP. 17 Safety and Efficacy Data: The CLEAR Trial

EP. 18 Common Adverse Events with Single-Agent or Combination Therapy

EP. 18 Common Adverse Events with Single-Agent or Combination Therapy

EP. 19 Balancing Treatment Efficacy with Toxicity in Metastatic RCC

EP. 19 Balancing Treatment Efficacy with Toxicity in Metastatic RCC

EP. 20 Strategies for Prevention and Management of Adverse Events

EP. 20 Strategies for Prevention and Management of Adverse Events

EP. 21 Patient-Specific Factors Impacting Treatment Choices in RCC

EP. 21 Patient-Specific Factors Impacting Treatment Choices in RCC

EP. 22 Considerations for Patient-Focused, Shared Decision-Making in RCC

EP. 22 Considerations for Patient-Focused, Shared Decision-Making in RCC

EP. 23 Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

EP. 23 Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

EP. 24 The Importance of Team-Based Management and Patient Communication

EP. 24 The Importance of Team-Based Management and Patient Communication

EP. 25 OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

EP. 25 OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

EP. 26 Reflections on Novel Targets and Emerging Regimens for RCC

EP. 26 Reflections on Novel Targets and Emerging Regimens for RCC

EP. 27 Clinical Pearls on Recent Advances and the Future of Treatment in RCC

EP. 27 Clinical Pearls on Recent Advances and the Future of Treatment in RCC

EP. 28 Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC

EP. 28 Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Zelenectide pevedotin demonstrated manageable safety among patients with advanced solid tumors in the phase 1/2 Duravelo-1 trial.

Zelenectide Pevedotin Displays Antitumor Activity in Advanced Solid Tumors

ByCancer Network Staff

January 25th 2026

According to investigators, the lack of anti-tumor activity and immunogenicity results do not support the agent’s further development in metastatic CRPC.

Phase 1 Study Evaluating JNJ-80038114 in Metastatic CRPC Discontinues Early

ByRoman Fabbricatore

January 17th 2026

Data from the QUILT-3.032 trial supported the Saudi approval of nogapendekin alfa plus BCG in adults with BCG-unresponsive NMIBC with carcinoma in situ.

Nogapendekin Alfa Combo Earns Saudi FDA Accelerated Approval in NMIBC Type

ByRoman Fabbricatore

January 16th 2026

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.

Highlighting the Million Strong Men Initiative for Prostate Cancer Screening

ByRoman Fabbricatore

January 14th 2026

Described as a “doctor’s office on wheels,” the mobile unit is Wi-Fi equipped and includes point of care PSA/imaging tests to help bring care to patients.

Prostate Screening Mobile Unit Success Spawns Million Strong Men Initiative

ByAsh Tewari, MD, MBBS, MCh, FRCS

January 13th 2026

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

19th Annual New York GU Cancers Congress™

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

In-Person + Virtual Event

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Addressing Unmet Needs in HER2+ Metastatic BTC

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Proactive Adverse Event Management for HER2+ BTC Treatments

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Trending on CancerNetwork

Cancer Vaccine Trial Receives FDA IND Clearance in Advanced Melanoma

FDA Approves Subcutaneous Daratumumab Combination in NDMM

Developers Resubmit NDA for Rivoceranib/Camrelizumab in Unresectable HCC

Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma

Urinary Cell-Free miR-93-5p/miR-191-5p Display Utility as NIMBC Biomarkers